Authors


Lewis C. Cantley, PhD

Latest:

Targeting PI3K Remains Complex in Cancer Therapy

Dr. Lewis Cantley discusses targeting the PI3K pathway in breast cancer and the importance of managing ambient insulin levels during therapy.


Chuan-Hsiang Huang, MD, PhD

Latest:

Interrogating Ras-ERK Interactions and Roles in Tumor Cell Biology

Cancer Network spoke with Dr. Chuan-Hsiang Huang about his lab’s research on Ras-ERK protein interactions within cancer cells.


Rachel Karchin, PhD

Latest:

Identifying Cancer-Driving Gene Mutations

Cancer Network spoke with Dr. Rachel Karchin about the contemporary search for cancer-driving gene mutations.


James Perry, MD

Latest:

Promising Glioma Therapy Options

Dr. James Perry speaks with Cancer Network about glioma therapy options and the future of brain cancer treatment.


Tracy D. Vannorsdall, PhD

Latest:

Discussing Advances in Chemo Brain Treatment

Cancer Network spoke with Tracy D. Vannorsdall, PhD and Patricia Ganz, MD about treatment methods for cancer-related cognitive impairment.


Patricia Ganz, MD

Latest:

Discussing Advances in Chemo Brain Treatment

Cancer Network spoke with Tracy D. Vannorsdall, PhD and Patricia Ganz, MD about treatment methods for cancer-related cognitive impairment.


Emily A. Lemke, DNP, AGPCNP-BC, AOCNP

Latest:

Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial Cancer

In this review, we discuss known data and the differences between the different immune checkpoint inhibitors, as well as future avenues to explore with immuno-oncologic agents in urothelial cancer.


Jianjun Gao, MD, PhD

Latest:

Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial Cancer

In this review, we discuss known data and the differences between the different immune checkpoint inhibitors, as well as future avenues to explore with immuno-oncologic agents in urothelial cancer.


Irene L. Wapnir, MD

Latest:

Current Strategies for the Management of Locoregional Breast Cancer Recurrence

In this review, we focus primarily on describing locoregional and systemic management strategies for isolated locoregional recurrences manifesting as isolated first-failure events following mastectomy or breast-conserving therapy.


Atif Khan, MD, MS

Latest:

Current Strategies for the Management of Locoregional Breast Cancer Recurrence

In this review, we focus primarily on describing locoregional and systemic management strategies for isolated locoregional recurrences manifesting as isolated first-failure events following mastectomy or breast-conserving therapy.


JoAnn Manson, MD, DrPH

Latest:

Vitamin D and Omega-3 Supplements for Preventing Cancer and Other Chronic Diseases

Dr. Manson discusses the results of the recently published VITAL study that tested whether vitamin D or omega-3 supplements could be effective for primary prevention of cancer and cardiovascular disease.


Naval Daver, MD

Latest:

Naval Daver, MD on Phase 1/2 Trial of DSP-5336 in R/R Acute Leukemia

A phase 1/2 trial assessed the use of menin inhibitor DSP-5336 in patients with acute leukemia overexpressing HOXA9 and MEIS1.


Adam J. Horn, MD

Latest:

Early Access to Electronic Health Records May Influence the Patient Experience

In a recent Hot Topics column, Mehmet Sitki Copur, MD, FACP, et al discussed the pros and cons of patients receiving test results early through electronic medical records.


Pornchai Jonglertham, MD

Latest:

Locally Advanced Rectal Cancer, What is the Standard of Care?

A 39-year-old Hispanic male presented with complaints of mucous stools, loss of appetite, rectal bleeding and a 30-pound weight loss within the past several months.


Kristina Frinzi Byers, PharmD, BCOP

Latest:

Management of Neutropenic Toxicity From CDK4/6 Inhibitors

An oncology pharmacist discusses how to manage neutropenic toxicity from treatment with CDK4/6 inhibitors for HR-positive breast cancer.


Omar Alhalabi, MD

Latest:

Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial Cancer

In this review, we discuss known data and the differences between the different immune checkpoint inhibitors, as well as future avenues to explore with immuno-oncologic agents in urothelial cancer.


Amishi Y. Shah, MD

Latest:

Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial Cancer

In this review, we discuss known data and the differences between the different immune checkpoint inhibitors, as well as future avenues to explore with immuno-oncologic agents in urothelial cancer.


Carmen Bergom, MD, PhD

Latest:

Using Radiation Therapy to Reduce Recurrence in DCIS

Cancer Network spoke with Dr. Carmen Bergom about advancements in the treatment of DCIS and the importance of using local recurrence patterns to help guide future research.


Hirva Mamdani, MD

Latest:

Adjuvant Durvalumab Beneficial in Esophageal/GEJ Cancer?

Cancer Network spoke with Dr. Hirva Mamdani about the role and efficacy of adjuvant durvalumab in patients with Esophageal/GEJ Cancer.


Ahmed Kaseb, MD

Latest:

Perioperative Immunotherapy the Future of HCC Treatment?

Cancer Network spoke with Dr. Ahmed Kaseb about a phase II pilot trial of perioperative immunotherapy for resectable HCC and how the results could change future perioperative treatment of the disease.


Daniela Molena, MD

Latest:

Endoscopic Resection Brings Excitement to Esophageal Cancer Treatment

Cancer Network spoke with Dr. Daniela Molena about the advancements in the treatment of esophageal cancer, including the safety and importance of endoscopic resection for the disease.


Bassel El-Rayes, MD

Latest:

The Next Steps Beyond Cytotoxic Chemo in Pancreatic Cancer

Cancer Network spoke with Dr. Bassel El-Rayes about novel strategies on the horizon for pancreatic cancer during the 2019 ASCO Gastrointestinal Cancers Symposium.


Michael F. Holick, MD, PhD

Latest:

Does Vitamin D Have a Role in Cancer Prevention?

Cancer Network spoke with Dr. Michael Holick about the role of and effectiveness of vitamin D in cancer prevention.


Christine C. Davis, PharmD, BCOP

Latest:

Nausea and Vomiting: Managing Side Effects From PARP Inhibitors

Here, two oncology pharmacists discuss the side effects of PARP inhibitor treatment, and how to prevent and treat nausea and vomiting in this patient population.


Sarah Caulfield, PharmD, BCOP

Latest:

Nausea and Vomiting: Managing Side Effects From PARP Inhibitors

Here, two oncology pharmacists discuss the side effects of PARP inhibitor treatment, and how to prevent and treat nausea and vomiting in this patient population.


Edward A. Copelan, MD

Latest:

CAR T-Cell Therapy in Non-Hodgkin Lymphoma Patients

Dr. Copelan discusses the use of chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma patients and how these therapies might improve upon the current standard of care.


Ebtesam Ahmed, PharmD, MS

Latest:

Antidepressants in Patients With Advanced Cancer: When They’re Warranted and How to Choose Therapy

In this article, we discuss the importance of screening for depression in cancer patients, as well as the available treatment options and their pros and cons.


Austin Lunney, BS

Latest:

Incidental Primary Squamous Cell Carcinoma of the Kidney Within a Calyceal Diverticulum Associated With Nephrolithiasis

A 64-year-old man is diagnosed with primary squamous cell carcinoma within the upper pole calyceal diverticulum of the kidney. What are the best steps of management?


Irfan Warraich, MD

Latest:

Incidental Primary Squamous Cell Carcinoma of the Kidney Within a Calyceal Diverticulum Associated With Nephrolithiasis

A 64-year-old man is diagnosed with primary squamous cell carcinoma within the upper pole calyceal diverticulum of the kidney. What are the best steps of management?


Joerg Herrmann, MD

Latest:

Detecting Cardiotoxicity in Cancer Patients Receiving VEGF Inhibitors

Dr. Herrmann discusses how to monitor and treat cardiotoxicity in cancer patients receiving VEGF inhibitors.